Teva Pharmaceutical Industries Ltd (TEVA)

49.47
0.80 1.59
NYSE : Health Care
Prev Close 50.27
Open 50.08
Day Low/High 49.30 / 50.57
52 Wk Low/High 48.01 / 66.55
Volume 6.10M
Avg Volume 5.77M
Exchange NYSE
Shares Outstanding 914.00M
Market Cap 47.04B
EPS 1.80
P/E Ratio 28.28
Div & Yield 1.36 (2.60%)

Latest News

Teva: This Is No Generic Downtrend

Teva: This Is No Generic Downtrend

There are no bullish divergences of consequence to suggest that the stock might be poised to rally.

Teva Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD)

Teva Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III registration trial studying the potential of SD-809 for the...

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc.

'Mad Money' Lightning Round: Don't Sell NRG Energy Just Yet

'Mad Money' Lightning Round: Don't Sell NRG Energy Just Yet

Cramer isn't selling AK Steel, Kellogg or Clorox.

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Worried about a bad event? There will be money coming off the sidelines afterward. Be prepared to buy on weakness.

Teva Announces Results From Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease

Teva Announces Results From Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announces top-line results from the exploratory Phase 2 PRIDE-HD study.

Bearish Bets: A Pharma, a Food Company and Other Stocks That Look Good Short

FNV, BFS, TEVA, SCX and UNFI were all recently downgraded by TheStreet’s Quant Ratings.

More Pharma and Tech Collaborations to Follow the Teva-Intel Wearable Device

Teva and Intel will develop a wearable device that monitors they symptoms of patients with Huntington disease.

Teva Strengthens Injectables Portfolio With The Launch Of An Authorized Generic Of Cubicin® (Daptomycin For Injection) In The United States

Teva Strengthens Injectables Portfolio With The Launch Of An Authorized Generic Of Cubicin® (Daptomycin For Injection) In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the launch of an authorized generic of Cubicin ®1 (daptomycin for injection) 500 mg per vial in the United States.

Buy These 5 Breakout Stocks

Buy These 5 Breakout Stocks

Here's a technical look at five stocks to trade for big breakout gains.

Teva To Develop Unique Wearable Tech And Machine Learning Platform For Continuous Measurement & Analysis Of Huntington Disease Symptoms In Collaboration With Intel

Teva To Develop Unique Wearable Tech And Machine Learning Platform For Continuous Measurement & Analysis Of Huntington Disease Symptoms In Collaboration With Intel

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announces a collaboration with Intel Corporation to develop a unique wearable device and machine learning platform for use in Huntington disease (HD).

5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

3 Reasons to Buy Teva Right Now

3 Reasons to Buy Teva Right Now

Teva, the worlds largest generic drug manufacturer, is currently looking like one of the best buys in the market.

Analysts' Actions -- Anthem, Chevron, DR Horton, Under Armour and More

Analysts' Actions -- Anthem, Chevron, DR Horton, Under Armour and More

Here are Tuesday's top research calls, including a downgrade for Anthem, an upgrade for DR Horton and new coverage on Chevron and Under Armour.

Cramer: We Need to Be Able to Predict a Clear Election Winner

Cramer: We Need to Be Able to Predict a Clear Election Winner

Without it, the uncertainty would be incredible between now and November.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: PFMT, UTSI, VBFC Downgrades: AMCN, BGG, CSTE, GBLI, NEWS, NTRA, SHLM, SUNS, TEVA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Will Teva Pharmaceuticals (TEVA) Stock Be Helped by Planned Launch of Generic EpiPen?

Will Teva Pharmaceuticals (TEVA) Stock Be Helped by Planned Launch of Generic EpiPen?

Teva Pharmaceuticals (TEVA) said it hopes to gain FDA approval by 2017 or 2018 for a generic EpiPen device.

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?

The Consumer Union is alleging that Mylan may have paid Teva to withhold its EpiPen competitor from the market.

5 Big Dividend Stocks Billionaire John Paulson Loves

5 Big Dividend Stocks Billionaire John Paulson Loves

Here's a closer look at five dividend stocks that Paulson & Co. owned in the most recently reported quarter.

Teva To Present Latest Data In Multiple Sclerosis At 2016 ECTRIMS Congress In London

Teva To Present Latest Data In Multiple Sclerosis At 2016 ECTRIMS Congress In London

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that data on COPAXONE ® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (MS), and laquinimod, an...

Mylan Still Isn't Cheap

Mylan Still Isn't Cheap

The EpiPen controversy makes this stock a shot in the dark.

How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

Teva To Present At The Wells Fargo 2016 Healthcare Conference

Teva To Present At The Wells Fargo 2016 Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Wells Fargo Healthcare Conference.

Teva Stock Higher on Ratings Upgrade

Teva Stock Higher on Ratings Upgrade

Teva stock rating was increased to 'outperform' with a $66 price target at Oppenheimer earlier today.

5 Health Care Stocks John Paulson Is Betting On in 2016

5 Health Care Stocks John Paulson Is Betting On in 2016

When it comes to investing in health care, hedge fund pro John Paulson knows his stuff.

Teva To Present New Respiratory Data At The 2016 European Respiratory Society (ERS) International Congress

Teva To Present New Respiratory Data At The 2016 European Respiratory Society (ERS) International Congress

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that five company-sponsored abstracts will be presented at the 2016 European Respiratory Society (ERS) International Congress in London, England on...

Teva To Host Generic Medicines Business Overview On September 9, 2016

Teva To Host Generic Medicines Business Overview On September 9, 2016

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.